nortriptyline has been researched along with Neuralgia in 28 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECTIVE (BACKGROUND): Amitriptyline (AT) is a standard therapy for postherpetic neuralgia (PHN)." | 9.08 | Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. ( Chipman, M; Reed, K; Vernich, L; Watson, CP, 1998) |
| "OBJECTIVE (BACKGROUND): Amitriptyline (AT) is a standard therapy for postherpetic neuralgia (PHN)." | 5.08 | Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. ( Chipman, M; Reed, K; Vernich, L; Watson, CP, 1998) |
| "First-line neuropathic pain drugs, including tricyclic antidepressants, are not always effective, and opioids have been recommended as second line." | 2.80 | Combination of morphine with nortriptyline for neuropathic pain. ( DuMerton-Shore, D; Gilron, I; Holden, RR; Jackson, AC; Tu, D, 2015) |
| "Despite many therapeutic options, painful diabetic neuropathy is still a common and challenging complication of diabetes mellitus and is often resistant to treatment with current modalities." | 2.74 | Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. ( Chehrei, A; Majidi, H; Siavash, M; Talaei, A, 2009) |
| "Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy." | 2.74 | Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Jackson, AC; Tu, D, 2009) |
| "Nortriptyline was effective in relieving NCP symptoms in patients with centralized component and insufficient response to other systemic and topical therapies who tolerated the drug for at least 4 weeks." | 1.56 | Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain. ( Cox, SM; Dieckmann, G; Hamrah, P; Morkin, MI; Ozmen, MC; Paracha, R; Rashad, R; Sanayei, N, 2020) |
| "We used a model of neuropathic pain induced by unilateral sciatic nerve cuffing." | 1.42 | κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain. ( Barrot, M; Bohren, Y; Doridot, S; Freund-Mercier, MJ; Gaveriaux-Ruff, C; Kieffer, BL; Megat, S; Yalcin, I, 2015) |
| "One of its consequences is neuropathic pain which is often chronic and difficult to treat." | 1.40 | The antiallodynic action of nortriptyline and terbutaline is mediated by β(2) adrenoceptors and δ opioid receptors in the ob/ob model of diabetic polyneuropathy. ( Barrot, M; Choucair-Jaafar, N; Freund-Mercier, MJ; Salvat, E, 2014) |
| "Neuropathic pain is pain arising as a direct consequence of a lesion or disease affecting the somatosensory system." | 1.39 | Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism. ( Barrot, M; Bohren, Y; Daniel, D; Fournel, S; Freund-Mercier, MJ; Hein, L; Hugel, S; Kremer, M; Megat, S; Petitjean, H; Schlichter, R; Tessier, LH; Yalcin, I, 2013) |
| "We used a murine model of neuropathic pain induced by sciatic nerve constriction to study the antiallodynic properties of a chronic treatment with the tricyclic antidepressants nortriptyline and amitriptyline." | 1.35 | Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. ( Barrot, M; Benbouzid, M; Freund-Mercier, MJ; Gavériaux-Ruff, C; Kieffer, BL; Muller, A; Tessier, LH; Waltisperger, E; Yalcin, I, 2008) |
| "The basis of the treatment of painful diabetic neuropathy is the use of drugs that block the transmission of pain (antineuritics) and a good metabolic control of underlying disease." | 1.33 | [Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy]. ( Bastías A, MJ; Olmos C, P; Toro C, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Bollenbach, M | 1 |
| Salvat, E | 3 |
| Daubeuf, F | 1 |
| Wagner, P | 1 |
| Yalcin, I | 6 |
| Humo, M | 1 |
| Letellier, B | 1 |
| Becker, LJ | 1 |
| Bihel, F | 1 |
| Bourguignon, JJ | 1 |
| Villa, P | 1 |
| Obrecht, A | 1 |
| Frossard, N | 1 |
| Barrot, M | 7 |
| Schmitt, M | 1 |
| Ahomäki, I | 1 |
| Böckerman, P | 1 |
| Pehkonen, J | 1 |
| Saastamoinen, L | 1 |
| Benavides, R | 1 |
| Vsevolozhskaya, O | 1 |
| Cattaneo, S | 1 |
| Zaykin, D | 1 |
| Brenton, A | 1 |
| Parisien, M | 1 |
| Verma, V | 1 |
| Khoury, S | 1 |
| Gilron, I | 4 |
| Diatchenko, L | 1 |
| Linciano, P | 1 |
| Rossino, G | 1 |
| Listro, R | 1 |
| Rossi, D | 1 |
| Collina, S | 1 |
| Barohn, RJ | 1 |
| Gajewski, B | 1 |
| Pasnoor, M | 1 |
| Brown, A | 1 |
| Herbelin, LL | 1 |
| Kimminau, KS | 1 |
| Mudaranthakam, DP | 1 |
| Jawdat, O | 1 |
| Dimachkie, MM | 1 |
| Iyadurai, S | 1 |
| Stino, A | 1 |
| Kissel, J | 1 |
| Pascuzzi, R | 1 |
| Brannagan, T | 1 |
| Wicklund, M | 1 |
| Ahmed, A | 1 |
| Walk, D | 1 |
| Smith, G | 1 |
| Quan, D | 1 |
| Heitzman, D | 1 |
| Tobon, A | 1 |
| Ladha, S | 1 |
| Wolfe, G | 1 |
| Pulley, M | 1 |
| Hayat, G | 1 |
| Li, Y | 1 |
| Thaisetthawatkul, P | 1 |
| Lewis, R | 1 |
| Biliciler, S | 1 |
| Sharma, K | 1 |
| Salajegheh, K | 1 |
| Trivedi, J | 1 |
| Mallonee, W | 1 |
| Burns, T | 1 |
| Jacoby, M | 1 |
| Bril, V | 1 |
| Vu, T | 1 |
| Ramchandren, S | 1 |
| Bazant, M | 1 |
| Austin, S | 1 |
| Karam, C | 1 |
| Hussain, Y | 1 |
| Kutz, C | 1 |
| Twydell, P | 1 |
| Scelsa, S | 1 |
| Kushlaf, H | 1 |
| Wymer, J | 1 |
| Hehir, M | 1 |
| Kolb, N | 1 |
| Ralph, J | 1 |
| Barboi, A | 1 |
| Verma, N | 1 |
| Ahmed, M | 1 |
| Memon, A | 1 |
| Saperstein, D | 1 |
| Lou, JS | 1 |
| Swenson, A | 1 |
| Cash, T | 1 |
| Ozmen, MC | 1 |
| Dieckmann, G | 1 |
| Cox, SM | 1 |
| Rashad, R | 1 |
| Paracha, R | 1 |
| Sanayei, N | 1 |
| Morkin, MI | 1 |
| Hamrah, P | 1 |
| Mi, W | 1 |
| Wang, S | 1 |
| You, Z | 1 |
| Lim, G | 1 |
| McCabe, MF | 1 |
| Kim, H | 1 |
| Chen, L | 1 |
| Mao, J | 1 |
| Ceredig, RA | 1 |
| Pierre, F | 1 |
| Doridot, S | 2 |
| Alduntzin, U | 1 |
| Gaveriaux-Ruff, C | 4 |
| Massotte, D | 1 |
| O'Sullivan, C | 1 |
| Froyman, C | 1 |
| Liu, WQ | 1 |
| Kanungo, A | 1 |
| Toth, C | 1 |
| Bohren, Y | 3 |
| Tessier, LH | 3 |
| Megat, S | 2 |
| Petitjean, H | 1 |
| Hugel, S | 1 |
| Daniel, D | 1 |
| Kremer, M | 1 |
| Fournel, S | 1 |
| Hein, L | 1 |
| Schlichter, R | 1 |
| Freund-Mercier, MJ | 5 |
| Choucair-Jaafar, N | 1 |
| Kieffer, BL | 3 |
| Derry, S | 1 |
| Wiffen, PJ | 2 |
| Aldington, D | 1 |
| Moore, RA | 2 |
| Miranda, HF | 1 |
| Noriega, V | 1 |
| Zepeda, R | 1 |
| Zanetta, P | 1 |
| Prieto-Rayo, J | 1 |
| Prieto, JC | 1 |
| Sierralta, F | 1 |
| Tu, D | 2 |
| Holden, RR | 2 |
| Jackson, AC | 2 |
| DuMerton-Shore, D | 1 |
| Rowbotham, MC | 1 |
| Talaei, A | 1 |
| Siavash, M | 1 |
| Majidi, H | 1 |
| Chehrei, A | 1 |
| Bailey, JM | 1 |
| Houlden, RL | 1 |
| Jensen, TS | 1 |
| Finnerup, NB | 1 |
| Karavelic, D | 1 |
| Chaparro, LE | 1 |
| Douglas, MW | 1 |
| Johnson, RW | 1 |
| Cunningham, AL | 1 |
| Bastías A, MJ | 1 |
| Toro C, L | 1 |
| Olmos C, P | 1 |
| Benbouzid, M | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Watson, CP | 1 |
| Vernich, L | 1 |
| Chipman, M | 1 |
| Reed, K | 1 |
| Stolar, AG | 1 |
| Stewart, JT | 1 |
| Taub, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)[NCT02260388] | Phase 4 | 402 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Topical Compounded Pain Creams And Pain Perception (TOPCAPP)[NCT01862848] | 285 participants (Actual) | Observational [Patient Registry] | 2012-11-30 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294] | 52 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome[NCT03463915] | Phase 3 | 90 participants (Actual) | Interventional | 2019-01-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 53.6 |
| Duloxetine | 55.4 |
| Pregabalin | 56.7 |
| Mexiletine | 51.6 |
"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 56.4 |
| Duloxetine | 56.5 |
| Pregabalin | 60.0 |
| Mexiletine | 54.5 |
"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 58.9 |
| Duloxetine | 58.9 |
| Pregabalin | 58.3 |
| Mexiletine | 59.1 |
"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks
| Intervention | Norm-Based Standardization Score (Mean) | |
|---|---|---|
| Mental Component Score | Physical Component Score | |
| Duloxetine | 50.9 | 42.1 |
| Mexiletine | 51.3 | 43.7 |
| Nortriptyline | 51.0 | 42.8 |
| Pregabalin | 47.2 | 40.0 |
Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | scores on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -6.7 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -5.8 |
VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -1.9 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -1.8 |
Adverse events will only be those determined to be related to the study drug (NCT03463915)
Timeframe: End of study (6 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 1 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 5 |
Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -24.2 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -18.8 |
20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -6.4 |
Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -2.7 |
Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | participants (Number) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 4 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 4 |
5 reviews available for nortriptyline and Neuralgia
| Article | Year |
|---|---|
Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Guanidines; Humans; Inflammatio | 2018 |
Sigma-1 receptor antagonists: promising players in fighting neuropathic pain.
Topics: Analgesics, Opioid; Animals; Humans; Methadone; Narcotic Antagonists; Neuralgia; Nortriptyline; Pate | 2020 |
Nortriptyline for neuropathic pain in adults.
Topics: Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanecarbox | 2015 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Tolerability of treatments for postherpetic neuralgia.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; | 2004 |
7 trials available for nortriptyline and Neuralgia
| Article | Year |
|---|---|
A functional polymorphism in the ATP-Binding Cassette B1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients.
Topics: Adrenergic Uptake Inhibitors; Aged; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily | 2020 |
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Topics: Adult; Aged; Analgesics; Bayes Theorem; Comparative Effectiveness Research; Duloxetine Hydrochloride | 2021 |
Equivalency of tricyclic antidepressants in open-label neuropathic pain study.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Drug Therapy, Combination; Female; Humans; Male; Mi | 2014 |
Combination of morphine with nortriptyline for neuropathic pain.
Topics: Adult; Affect; Aged; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Constipation; Double-Blin | 2015 |
Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Anticonvulsants; Antidepressive Agents, Tricyclic; Bloo | 2009 |
Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
Topics: Administration, Oral; Aged; Amines; Analgesics; Antidepressive Agents, Tricyclic; Canada; Cross-Over | 2009 |
Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial.
Topics: Aged; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cross-Over Studies; Depre | 1998 |
16 other studies available for nortriptyline and Neuralgia
| Article | Year |
|---|---|
Effect of Information Intervention on Prescribing Practice for Neuropathic Pain in Older Patients: A Nationwide Register-Based Study.
Topics: Aged; Amitriptyline; Drug-Related Side Effects and Adverse Reactions; Humans; Inappropriate Prescrib | 2023 |
Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Eye Pain; Female; Huma | 2020 |
Nortriptyline Enhances Morphine-Conditioned Place Preference in Neuropathic Rats: Role of the Central Noradrenergic System.
Topics: Adrenergic Neurons; Analgesics, Opioid; Animals; Conditioning, Operant; Drug Therapy, Combination; M | 2017 |
Peripheral delta opioid receptors mediate duloxetine antiallodynic effect in a mouse model of neuropathic pain.
Topics: Animals; Antidepressive Agents, Tricyclic; Disease Models, Animal; Duloxetine Hydrochloride; Female; | 2018 |
Nortriptyline safer than amitriptyline?
Topics: Amitriptyline; Canada; Consensus; Humans; Neuralgia; Nortriptyline | 2018 |
Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, M | 2013 |
The antiallodynic action of nortriptyline and terbutaline is mediated by β(2) adrenoceptors and δ opioid receptors in the ob/ob model of diabetic polyneuropathy.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Diabetic Neuropathies; D | 2014 |
κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.
Topics: Animals; Antidepressive Agents, Tricyclic; Male; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Neu | 2015 |
Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Synergism; Drug Therapy, Combination; | 2015 |
Tricyclic antidepressants and opioids-better together?
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Female; Humans; Male; Morphine; Neuralgia; Nor | 2015 |
Neuropathic pain treatment: a further step forward.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Male; Mice; Mice, Knockout; Morphine; N | 2010 |
[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy].
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Clomipramine; Cyclohexanecarboxylic A | 2006 |
Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Disease Models, Animal; Dose-Response Rela | 2008 |
Nortriptyline for depression and vulvodynia.
Topics: Aged; Chronic Disease; Depressive Disorder, Major; Female; Humans; Neuralgia; Nortriptyline; Treatme | 2002 |
Relief of postherpetic neuralgia with psychotropic drugs.
Topics: Aged; Amitriptyline; Analgesics; Antidepressive Agents; Antipsychotic Agents; Female; Fluphenazine; | 1973 |